AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. - sprookjes - yvandenbroek - TriplyDB

AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.

AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.

http://www.wikidata.org/entity/Q38996033

about

Growth inhibition of human gastric adenocarcinoma cells in vitro by STO-609 is independent of calcium/calmodulin-dependent protein kinase kinase-beta and adenosine monophosphate-activated protein kinase High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer Triptolide exerts pro-apoptotic and cell cycle arrest activity on drug-resistant human lung cancer A549/Taxol cells via modulation of MAPK and PI3K/Akt signaling pathways.miRNA-34a enhances the sensitivity of gastric cancer cells to treatment with paclitaxel by targeting E2F5.Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells.SNP rs3202538 in 3'UTR region of ErbB3 regulated by miR-204 and miR-211 promote gastric cancer development in Chinese population.Connexin 43 enhances paclitaxel cytotoxicity in colorectal cancer cell lines.Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT/MAPK signaling pathway in canine mammary gland tumor cells.Pegylated liposomal‑paclitaxel induces ovarian cancer cell apoptosis via TNF‑induced ERK/AKT signaling pathway.microRNA-23a promotes cell growth and metastasis in gastric cancer via targeting SPRY2-mediated ERK signaling.Long non-coding RNA GAS5 inhibits ovarian cancer cell proliferation via the control of microRNA-21 and SPRY2 expression.

P2860

Q28393172-D102C363-7AD5-4694-8C39-DC146D75987C Q35406015-E299903B-28DC-4A89-BAF1-8BB28BE30C27 Q35440276-1AA53B1A-5C87-4D91-B304-26347367C652 Q37407088-CC4B30DD-4B2B-4205-BE77-1E7052AF4223 Q38733764-608C9F4B-E464-4747-B5F0-FF9D2E551E21 Q38810143-9130FE97-F5BF-460F-9744-C5427D1389E3 Q41036589-1772F99A-1F22-4769-AFA2-A237D89997A4 Q41116432-3D76838F-FE42-4982-8C95-B2EC21F8CC62 Q52719198-E4D517FF-1EF8-4930-8CA6-4D9320659003 Q54117497-F27A6FE8-6C6E-42B0-A570-19A4D2E63F1E Q54966153-2DE9F433-9F46-4EA5-8CCB-7973546570AE Q55284142-980FC7FE-804B-46DE-9E1C-0172CAF77321

P2860

AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.

http://www.wikidata.org/entity/Q38996033

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.

@en

type

label

AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.

@en

prefLabel

AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.

@en

P1433

Q38996033-E8424C24-DD24-45E3-9EDE-D449D6736D38

P1476

Q38996033-9613ACF5-EC53-492D-8274-66768E25B1EC

P2093

Q38996033-21964D1F-A123-4F77-9566-C4EF1F14D9B7

Q38996033-318903F4-2A04-417F-A0F9-8042E590F6AD

Q38996033-9703C59D-E636-4BCA-B4ED-98C97FCE5AC8

Q38996033-DB4A7C62-9296-4299-910B-41053444DE34

Q38996033-E2B0FBC7-C17F-4465-9F1E-E00E1297F4B3

P2860

Q38996033-02DB80F5-F222-4347-97F6-59147023909B

Q38996033-06E9C7C7-AFD4-49DF-96FB-B0C35CBFE8E5

Q38996033-15E2985C-4AD2-4FCA-B683-BF12B23A0FAB

Q38996033-17562853-FF12-43FD-A379-70C5D302CAAB

Q38996033-1F494F2D-B11C-4122-801B-CB3A3AA6D052

Q38996033-248F9EC4-586D-47BA-AFAF-7464337A1CB8

Q38996033-2A0806C8-98CD-45BD-9DBF-8320A15CD4FB

Q38996033-30783317-645A-4356-896A-7B8A9798F5BF

Q38996033-32C50470-57FB-425F-B786-9A88E6943490

Q38996033-34BA6CED-4729-4DFB-AF58-E77119BBE36B

P304

Q38996033-ADC448C2-73F3-49FB-A2C5-1C24C3D2E76A

P31

Q38996033-5C4FED9D-7862-4111-BFEF-16966B41F548

P433

Q38996033-D40F592F-5FE3-4EB4-BAA3-3103B02671E6

P478

Q38996033-6AB89FEC-2A58-401D-874F-107901B86B8B

P577

Q38996033-DFD10596-E15A-46DC-AAA7-437944F0FF17

P698

Q38996033-F76B1053-D339-4E19-BB07-483F9DBC8B76

P932

Q38996033-69511FE7-21E5-4BF8-8D26-2DA95EF208A5

P1433

International Journal of Clinical and Experimental Pathology

P1476

AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.

@en

P2093

Gang Wu

http://www.w3.org/2001/XMLSchema#string

Jin-Hong Chen

http://www.w3.org/2001/XMLSchema#string

Jing-Jing Guo

http://www.w3.org/2001/XMLSchema#string

Tian-Yi Li

http://www.w3.org/2001/XMLSchema#string

Xue-Qian Qin

http://www.w3.org/2001/XMLSchema#string

P2860

Significance analysis of microarrays applied to the ionizing radiation response

Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin

Gene silencing by microRNAs: contributions of translational repression and mRNA decay

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.

Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.

Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.

P304

1449-1458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24817940

http://www.w3.org/2001/XMLSchema#string

P932

4014224

http://www.w3.org/2001/XMLSchema#string